Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) – Pipeline Review, H2 2017’, provides in depth analysis on Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders and Oncology under development targeting Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects

The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

3SBio Inc

Boehringer Ingelheim GmbH

Clementia Pharmaceuticals Inc

Galderma SA

Lee's Pharmaceutical Holdings Ltd

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

Valeant Pharmaceuticals International Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview 7

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development 20

3SBio Inc 20

Boehringer Ingelheim GmbH 20

Clementia Pharmaceuticals Inc 20

Galderma SA 21

Lee's Pharmaceutical Holdings Ltd 22

Phosphagenics Ltd 22

Promius Pharma LLC 22

Sol-Gel Technologies Ltd 23

Valeant Pharmaceuticals International Inc 23

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles 25

(adapalene + clindamycin hydrochloride) - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

(benzoyl peroxide + tretinoin) - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

(clindamycin phosphate + tretinoin) - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

adapalene + benzoyl peroxide + clindamycin phosphate - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

alitretinoin - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

bexarotene + CD1530 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

palovarotene - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules to Agonize RARG for Fibrosis - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

tazarotene - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

tazoretene - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

TPX-6001 + tretinoin - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

tretinoin - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

tretinoin - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

trifarotene - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

vitamin A palmitate - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

vitamin A palmitate - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products 53

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products 55

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones 56

Featured News & Press Releases 56

Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September 56

Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris 57

Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children’s Bone Health 57

Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends 58

Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva 59

Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study 60

Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia’s Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP) 60

Jun 09, 2016: Galderma Trifarotene Development Program Meets Key Milestone for Lamellar Ichthyosis Orphan Disease 61

Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day 62

Apr 14, 2016: Positive Effects of Palovarotene on Spontaneous Heterotopic Ossification, Mobility, and Skeletal Growth in Mouse Models of FOP Reported in Journal of Bone and Mineral Research 63

Feb 29, 2016: Clementia Announces Last Patient Enrolled in Phase II trial of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva 64

Jan 21, 2016: GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program 64

Aug 25, 2015: Clementia Pharmaceuticals Expands Ongoing Phase 2 Study to Include Children with Fibrodysplasia Ossificans Progressiva 65

May 28, 2015: Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 65

Apr 02, 2015: Clementia Advances Phase 2 Clinical Trial of Palovarotene in Fibrodysplasia Ossificans Progressiva Based on Recommendations from Data Monitoring Committee 66

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by 3SBio Inc, H2 2017 20

Pipeline by Boehringer Ingelheim GmbH, H2 2017 20

Pipeline by Clementia Pharmaceuticals Inc, H2 2017 21

Pipeline by Galderma SA, H2 2017 21

Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 22

Pipeline by Phosphagenics Ltd, H2 2017 22

Pipeline by Promius Pharma LLC, H2 2017 23

Pipeline by Sol-Gel Technologies Ltd, H2 2017 23

Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 24

Dormant Products, H2 2017 53

Dormant Products, H2 2017 (Contd..1), H2 2017 54

Discontinued Products, H2 2017 55

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports